IFNA4

expressed in E. coli

70-95% (SDS-PAGE)

lyophilized powder

~19.6 kDa

P05014

dry ice

−70℃

human ... IFNA4(3441)

Recombinant Human IFNA4 was expressed in E. coli cells. All known subtypes of IFN- alpha show the same antiviral antiparasitic, antiproliferative activities. IFN-alpha forms are produced by monocytes/macrophages, lymphoblastoid cells, fibroblasts, and a number of different cell types following induction by viruses, nucleic acids, glucocorticoid hormones, and low-molecular weight substances. All IFN-alpha subtypes possess a common conserved sequence region between amino acid positions 115-151 while the amino-terminal ends are variable. Many IFN-alpha subtypes differ in their sequences at only one or two positions. IFN-alpha and IFN-beta are thought to bind to the same receptor. Signal transduction mechanisms elicited after binding of IFN-alpha to its receptors involves tyrosine phosphorylation (see also: PTK; protein tyrosine kinase) of various non-receptor tyrosine kinases belonging to the Janus kinases.

Formulated as a lyophilized protein from a 0.2 um filtered solution in Tris and NaCl, pH 8.0. Upon reconstitution, working aliquots can be stored at 2-8℃ for one month, or at -20℃ for six months, with a carrier protein without detectable loss of activity.

The lyophilized protein is stable for at least one year from date of receipt at -70℃. Upon reconstitution, this cytokine can be stored in working aliquots at 2-8℃ for one month, or at -20℃ for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.

10 - Combustible liquids

WGK 1